Tetraphase Pharmaceuticals to Present at 2016 JMP Securities Life Sciences Conference

WATERTOWN, Mass., June 15, 2016 (GLOBE NEWSWIRE) -- Tetraphase Pharmaceuticals, Inc. (NASDAQ: TTPH), a clinical stage biopharmaceutical company developing novel antibiotics to treat life-threatening multidrug-resistant (MDR) infections, today announced that company management will give a corporate presentation at the JMP Securities Life Sciences Conference on Wednesday, June 22, 2016 at 1:30 p.m. Eastern Time at The St. Regis New York Hotel in New York City.

A live audio webcast of the JMP presentation will be available on the company's website at http://ir.tphase.com/events.cfm.  An archived presentation will be available for 30 days.

About Tetraphase Pharmaceuticals, Inc.Tetraphase is a clinical-stage biopharmaceutical company using its proprietary chemistry technology to create novel antibiotics for serious and life-threatening bacterial infections, including those caused by many of the multidrug-resistant (MDR) bacteria highlighted as urgent public health threats by the CDC. Tetraphase has created more than 3,000 novel tetracycline analogs using its proprietary technology platform. Tetraphase's pipeline includes eravacycline, its lead antibiotic candidate in phase 3 clinical trials, as well as two additional antibiotic candidates, TP-271 and TP-6076. Please visit www.tphase.com for more company information.

Investor Contacts:
Tetraphase Pharmaceuticals
Teri Dahlman
617-600-7040
[email protected]

Argot Partners
Susan Kim
212-600-1902
[email protected]

Media Contact:
Sam Brown Inc.
Mike Beyer
312-961-2502
[email protected]

You May Also Be Interested In

• How Minecraft's Creator Economy Keeps Growing After 17 Years
• App Development Costs Drop From $200,000 to Near $50,000 as Chop Dawg Pairs AI-Accelerated Engineering With 18 Years of Discipline
• 2026 AI Creator Festival Concludes in Bali: Wan3.0 and Global Creators Explore the New Frontier of AI Video Generation